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Abstract 
Laboratorios Andrómaco was a Spanish pharmaceutical company that opened a commercial subsidiary 
in the United States in the early months of 1928. It was located right in the heart of Manhattan, at 11 
West 42
nd
 Street, in front of the New York Public Library. Despite the Wall Street crash, it remained 
open until 1946. The owner was the pharmacist-entrepreneur Fernando Rubió Tudurí (1900–1994). It 
was the first foreign direct investment made by a Spanish pharmaceutical multinational in the United 
States, using a maquila-style operation to export Spanish products made in the USA to Central 
American markets. Nothing has been published about this until now. Only interviews with Enrique 
and Mercè Rubió Boada (son and daughter of Fernando Rubió), digitalized sources from the company 
held by the Fundació Rubió Tudurí in Mahón, Minorca, and hard-to-access secondary sources have 
made the recovery of this history possible. The company closed its doors in the US and expanded in 
South American markets after World War II, but the short history of their investment in the United 
States reveals the potential and international capabilities of Spanish pharmaceutical companies before 
the Spanish Civil War. Moreover, it reveals how the Spanish Civil War was a disaster for millions of 
people but in some special cases it became an opportunity for companies in the science industries. Few 
pharmaceutical firms like Andrómaco, with entrepreneurs, resources, and a long-term vision, took the 
decision to invest in the most profitable (though also the most difficult) market for pharmaceutical 
products in the world: the United States. Andrómaco was created in Barcelona in 1923 by two 
scientist-entrepreneurs (Raul Roviralta and Fernando Rubió Tudurí). A nutritional product called 
                                                          
1
 This research is ongoing and has been made possible thanks to the Fundación BBVA’s I Ayudas a la 
Investigación en Socio-economía (2014–2016), within the research project ‘Multinacionales innovadoras 
españolas en Estados Unidos y Alemania’ (Innovative Spanish multinationals in the United States and 
Germany).  
 
Corresponding author. E-mail: palomafernandez@ub.edu 
Received 23 June 2016 - Accepted 04 July 2016     
 
Volume 2, Number 1, 266-275, July-December 2016           doi.org/10.1344/JESB2016.2.j019 
 
Online ISSN: 2385-7137                                                                                                      COPE Committee on Publication Ethics 
http://revistes.ub.edu/index.php/JESB  Creative Commons License 4.0      
267 
Glefina (made with Norwegian cod oil from Ålesund and sugar) brought the small firm considerable 
success in sales in Spain in the mid-1920s. Making use of impressive networks (with the Spanish royal 
family, Catalan political elites, and the medical and pharmaceutical profession in Spain and Germany) 
and innovative commercial approaches (sending free samples to selected clients like King Alfonso 
XIII’s family circle and Dr Gregorio Marañón) were key business strategies during those years. The 
commercial subsidiary had two employees that coordinated the outsourcing of the production to local 
US producers, with exports of their US-made Andrómaco products going to Central American clients. 
Those clients loved buying a US-made product designed and sold by a Spanish pharmacist living in 
Long Island, with an office in Manhattan, who frequently travelled from the US to Latin America in 
the tough years of the Depression. 
Keywords: Laboratorios Andrómaco; Spanish Multinationals; Pharmaceutical Industry; History of 
Pharmaceutical FDI 
 
Today, Laboratorios Andrómaco is well-known as one of the most important pharmaceutical 
corporations in Argentina, and Andrómaco also exists as one of the leading pharmaceutical 
corporations in Mexico. They are, despite sharing the same name, independent companies, 
heirs of Laboratorios Andrómaco, a Spanish pharmaceutical corporation founded in 
Barcelona, Spain, in 1923 by Raul Roviralta and Fernando Rubió Tudurí. The company was 
one of the most successful laboratories before the Spanish Civil War and the partners were 
two of the most outward-looking pharmaceutical entrepreneurs in the country, opening 
subsidiaries in Lisbon in 1926, Buenos Aires in 1927, and in Cuba, New York, Montevideo, 
São Paulo, and Caracas in 1928. The Civil War in Spain caused the partners and their families 
to leave the country and move to where their subsidiaries were located. Raul Roviralta moved 
to Buenos Aires, taking control of the lab’s South American businesses. Fernando Rubió 
Tudurí moved to New York and from his 5
th
 Avenue office in Manhattan he controlled the 
production of their products in the United States and their exports to Cuba, Santo Domingo, 
and Guatemala with the label Andrómaco USA. The company was particularly outstanding in 
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the design of pharmaceutical products with relatively low production costs and prices but with 
great demand, such as Glefina (a nutritional product based on cod oil and sugar) and a cream 
for skin rashes known as Halibut in Spain and Lassar in North, Central, and South America. 
The founders were also remarkable for their innovative commercial strategies and their global 
outward-looking attitude: most of the subsidiaries and the commercial network were set up 
between the 1920s and the 1940s. The great expansion of their company took place during 
these very difficult years, with products adapted to the scarcity and low purchasing power of 
the times, and with a relatively simple organizational structure (rapid creation of commercial 
subsidiaries under control of managers linked to them through trust-based agreements).  
Andrómaco is interesting for these reasons, but also because it was the first Spanish 
pharmaceutical company that dared to open a subsidiary at the heart of the global 
pharmaceutical industry market, the United States, in 1928. Not many companies in 
developing economies, particularly in science-based industries, dare to sell anything in the 
markets where global innovation takes place and the major industry players are located. 
Academic international business models often indicate that companies in developing 
economies usually develop through a gradual process where they first learn and transfer 
knowledge on international operations from developed economies and leading corporations in 
an industry using different mechanisms, including imports and business trips. According to 
these gradual academic models of internationalization, a second step for these kinds of 
companies is to try to export to psychologically similar markets to reduce uncertainty and 
risk. And in the final stage they may, or may not, try to export and invest in more difficult 
markets, but rarely the most developed and regulated markets where the toughest competitors 
in the world are located. Andrómaco is one of the cases that challenge the academic models. 
 
Volume 2, Number 1, 266-275, July-December 2016           doi.org/10.1344/JESB2016.2.j019 
 
Online ISSN: 2385-7137                                                                                                      COPE Committee on Publication Ethics 
http://revistes.ub.edu/index.php/JESB  Creative Commons License 4.0      
269 
Laboratorios Andrómaco accumulated sales, knowledge, social networks, and human capital 
between 1923 and 1928. The founders were recent graduates in Pharmacy and Chemistry, 
belonged to the upper middle classes of Barcelona, and had an excellent social network 
among the upper middle classes beyond Barcelona and in the medical profession. Rubió 
Tudurí’s father was a military civil engineer who graduated from the Academy of Guadalajara 
and his brothers were outstanding architects and politicians (Mariano and Nicolas Rubió 
Tudurí), who were well-connected to local Catalanist political leaders like Francesc Maciá 
and Lluis Companys, and to local real estate businessmen. Rubió Tudurí’s father worked, like 
one of his sons, in the urbanization of Barcelona linked to the International Exposition of 
1929, participating in the design and construction of infrastructures in Plaça d’Espanya, 
Montjuїc, and the Tibidabo Mountain.  
Rubió Tudurí and Roviralta were neighbours and had important pharmacist-entrepreneurs 
living nearby, including friends of their families such as Dr Salvador Andreu and Dr Antoni 
Esteve.  
Post-graduate studies in Madrid granted Rubió Tudurí the opportunity to help the personal 
doctor of the king’s children and he met the royal family. His post-graduate studies at the 
Institut Pasteur in Paris also allowed Rubió Tudurí to meet renowned European scientists that 
would help him in the future when he had to move to the United States due to war. 
Laboratorios Andrómaco’s success started with the production of Glefina (1924–1960s), 
made with cod oil imported from the Norwegian town of Ålesund, where dozens of cod oil 
exporters concentrated a huge level of production in the 1920s (Jonsson 2006). The success of 
this product and its consumption and recommendations to consume it by the entire royal 
family and the famous Dr Gregorio Marañón led the partners to decide to expand their market 
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beyond Spain, opening their first commercial subsidiary in Lisbon in 1926 and a factory in the 
same city in 1931. The positive prospects, the extraordinary self-confidence of the partners, 
and the social networks through which privileged information circulated made them take the 
decision to invest outside Europe, first in Buenos Aires in 1927 and then in Central America. 
While negotiating the opening of a subsidiary in Cuba, Rubió Tudurí had to stop off in New 
York in 1928, and he was left wide-eyed at the sight of the luxurious atmosphere of 
consumption in the city. He was used to dealing with the Spanish upper classes and their 
consumption habits, as well as taking care of presentation and commercialization with labels, 
boxes, advertisements, and the personal care of clients, and so he took the decision to open a 
subsidiary in New York and to try to sell the products in the United States, right before the 
Wall Street crash of 1929. One wonders whether this was a wise decision considering future 
developments, but the fact is that the lab’s products were made with relatively cheap raw 
materials, the profit margins were very high, and the employment costs were relatively low. 
Rubió Tudurí believed that by outsourcing the production of his nutritional products to US 
producers, a maquila-style operation, he would certainly save on transportation costs and have 
good quality production. The quality achieved thanks to the suppliers’ US production 
facilities was much appreciated by Central American clients in Cuba, Santo Domingo, and 
Guatemala, who according to Enrique Rubió Boada, Fernando Rubió Tudurí’s son, ‘loved’ 
buying a US-made Spanish product sold by a Spanish-speaking entrepreneur. Rubió Tudurí 
was not afraid of the financial crash and probably (though we have no information to back 
this hypothesis so far) it was perceived as an opportunity to have more US companies ready to 
serve the Spanish lab at lower prices, as well as to manufacture and to transport the products 
in US ships to Central America. 
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Rubió Tudurí hired two people for his commercial office in Manhattan. The manager was a 
German named Unger who had worked in the Barcelona International Exposition of 1929 in 
which Rubió’s father had also worked as a civil engineer. Unger was fluent in German, 
Spanish (married to an Andalusian woman), and English, and had a strong commercial profile 
and expertise. Unger would be Rubió’s right hand man in New York while he travelled to 
meet Central and South American clients. Unger was also in charge of administering a 
warehouse where products manufactured by US suppliers were kept until their final export to 
clients in Central America, Cuba, Guatemala, or Santo Domingo, in a maquila-style 
operation. A secretary who lived in New York was also employed to handle administrative 
tasks. While the office was managed by Unger and the secretary, Rubió travelled to find 
suppliers in the US and to meet and take care of old and new clients in Central America but 
also in Colombia, Mexico, and Canada. Rubió’s family was installed in a house on Long 
Island, and they frequently met other Spanish refugees from the Civil War such as Dr Duran 
Reynalds, who worked in the Rockefeller Institute, and many Catalan politicians and 
businessmen.  
The end of the first US subsidiary of this Spanish pharmaceutical company took place 
between 1946 and 1949. For personal and professional reasons, Rubió Tudurí moved to 
Colombia and then to Mexico City where he concentrated his activities and businesses. 
Further research will have to explore North American archives to discover more about this 
unique company. A hard-to-answer counterfactual question could be what would have 
happened if the Civil War had not taken place? Maybe the example of Andrómaco in the 
United States could have attracted more Spanish pharmaceutical companies to Manhattan. 
And maybe the era of internationalization of the Spanish pharmaceutical industry would have 
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 century and not the late 20
th
 century as subsequent events have shown us to 
be the case. Andrómaco was a visionary company and, therefore, it opened new pathways to 
internationalization for innovative companies in Spain. The war and the Francoist dictatorship 
blocked these pathways and slowed down the entire industry. 
Selected chronology 
1923: Establishment of Laboratorios Andrómaco in Barcelona by founding partners Raul 
Roviralta and Fernando Rubió Tudurí.   
1924: Commercial distribution of nutritional product GLEFINA based on cod oil imported 
from Ålesund in Norway and toasted sugar (following the advice of Rubió Tudurí’s mother to 
improve the taste). Samples were distributed for free among the political elite, the royal 
family, and the elite of the medical and pharmaceutical professions. Commercialization was a 
success up until the 1960s when a variety of multivitamin products from foreign 
multinationals began to spread. 
1926: Opening of Laboratorios Andrómaco commercial office in Lisbon. 
1927: Opening of Laboratorios Andrómaco commercial office in Buenos Aires. 
1928: Opening of Laboratorios Andrómaco commercial offices in Cuba, New York, 
Montevideo, São Paulo, and Caracas. 
1929: Fernando Rubió is CEO of Laboratorios Andrómaco’s subsidiaries in North America, 
Central America, and Mexico, with headquarters in New York.  
1931: Opening of a Laboratorios Andrómaco factory in Lisbon. 
1938–1975: The two founding partners left Spain with their families and left C. Matjí, a 
relative of Rubió, in charge of the factory in Barcelona. Roviralta moved to the subsidiary in 
Buenos Aires and Rubió to the subsidiary in New York. They split the ownership and 
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management of the company. Fernando Rubió Tudurí kept subsidiaries in Colombia, the 
United States, Portugal, and Mexico. Raul Roviralta kept the rest of South America 
(Argentina, Chile, Brazil, and Uruguay) with headquarters in Buenos Aires. The Spanish 
subsidiary would remain owned by both founding partners, half each, and was managed by C. 
Matjí first in Barcelona and then in Madrid until its gradual sale to the German Grünenthal 
between the 1970s and the 1990s. The name Andrómaco was maintained by Rubió Tudurí. 
Rubió Tudurí gave autonomy to all of his subsidiaries (Barcelona, Madrid, Mexico, Paris, 
Lisbon, New York, Montreal, Havana, Bogotá, São Paulo), under his coordination first in 
New York until 1946 and from then onwards in Colombia and Mexico.  
1968: Opening of Andrómaco Building in Colombia.  
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